Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07416552 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
MinorStart date pushed from Sep 8, 2026 to Oct 6, 2026Study sites: 3 to 5 · Eligibility criteria expanded, about 18 wordsShow 2 more changesShow less
Study sites: 3 to 5
Eligibility criteria expanded, about 18 words
MinorStudy sites: 2 to 3v8
NotableRecruitment openedStart date: Jul 31, 2026 to Sep 8, 2026 · Study sites: 1 to 2v7Show 2 more changesShow less
Start date: Jul 31, 2026 to Sep 8, 2026
Study sites: 1 to 2
NotableStart date: Jun 16, 2026 to Jul 31, 2026Trial status changed: Recruiting → Not Yet Recruiting · Site details revisedv6Show 2 more changesShow less
Trial status changed: Recruiting → Not Yet Recruiting
Site details revised
NotableStart date: May 12, 2026 to Jun 16, 2026v5
MinorStart date: Apr 21, 2026 to May 12, 2026v4
NotableRecruitment openedStudy sites: 0 to 1 · Start date: Mar 31, 2026 to Apr 21, 2026v3Show 2 more changesShow less
Study sites: 0 to 1
Start date: Mar 31, 2026 to Apr 21, 2026
MinorRe-verified, no change to tracked fieldsv2
MinorStudy First Submitted
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will evaluate the dosimetry, safety, efficacy, pharmacokinetics (PK), pharmacodynamics and immunogenicity of CEA-PRIT 2.0 in participants with metastatic microsatellite-stable (MSS) mCRC who are intolerant to or have progressed after having received available standard-of-care (SOC) therapies.